Treace Medical Concepts Reports Third Quarter 2026 Financial Results
Lower operating expenses narrowed quarterly losses despite declining revenue, and Treace reduced its expected full-year adjusted EBITDA loss.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Treace Medical Concepts (TMCI) reported third-quarter 2026 revenue of $48.3 million, down 4% from the same quarter in 2025. Treace attributed the decline mainly to a shift toward lower-priced minimally invasive products and fewer bunion procedure kits sold. Net loss narrowed to $12.6 million, or $0.19 per share, from $16.3 million, or $0.26 per share. Operating expenses fell 10% to $49.9 million, while adjusted EBITDA turned positive at $0.3 million.
Treace now expects full-year revenue of $206 million to $210 million, versus $204 million to $212 million previously, representing a 3% to 1% decline from 2025. It reduced its expected adjusted EBITDA loss to $1 million to $2 million from $3 million to $5 million and reiterated approximately 50% lower cash usage. Year-to-date cash usage fell 53%, or $9.7 million. Cash, cash equivalents and marketable securities totaled $39.8 million at September 30, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter net loss narrowed to $12.6 million, or $0.19 per share, versus $16.3 million, or $0.26.
- Moderate pointThird-quarter adjusted EBITDA improved $2.9 million to $0.3 million, versus a $2.6 million loss in 2025.
- Moderate pointThird-quarter operating expenses fell 10% to $49.9 million from $55.4 million in 2025.
- Moderate pointYear-to-date cash usage decreased 53%, or $9.7 million, versus the same period in 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 adjusted EBITDA loss expected at $1 million to $2 million, versus $3 million to $5 million previously.
- Moderate pointThird-quarter procedure volume achieved double-digit growth.
- Moderate pointExisting credit facility provides up to an additional $115 million of borrowing capacity. 42% of market cap
6 minor points
- Minor pointThird-quarter gross margin increased to 79.5% from 79.1% in 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 cash usage expected to decline approximately 50% versus 2025, reiterating prior expectations.
- Minor pointThird-quarter revenue excluding stocking distributors grew mid-single digits year over year, with increased bunion kit volume.
- Minor pointExpanded bunion-system adoption reached approximately 45% of Lapiplasty surgeon users, versus 40% in second-quarter 2026.
- Minor pointNine-month net loss narrowed to $46.400 million, or $0.71 per share, versus $49.608 million, or $0.79.
- Minor pointNine-month operating expenses declined to $155.021 million from $167.583 million in 2025.
Negative
- Moderate pointThird-quarter revenue fell 4% to $48.3 million, reflecting lower-priced product mix and fewer bunion kits sold.
- Moderate pointStockholders’ equity fell to $61.646 million at September 30, 2026, from $87.332 million at year-end 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.Full-year revenue guidance narrowed to $206 million–$210 million from $204 million–$212 million, implying a 3%–1% annual decline.
- Minor pointThird-quarter gross profit declined to $38.4 million from $39.7 million in 2025.
- Minor pointAdditional borrowing capacity of up to $115 million remains subject to certain conditions.
5 minor points
- Minor pointNine-month revenue declined to $140.827 million from $150.171 million in 2025.
- Minor pointNine-month gross profit fell to $111.364 million from $119.351 million in 2025.
- Minor pointThird-quarter interest expense rose to $1.584 million from $1.338 million in 2025.
- Minor pointNine-month interest expense rose to $4.716 million from $3.970 million in 2025.
- Minor pointLong-term debt, net, increased to $56.264 million at September 30, 2026, from $55.583 million at year-end 2025.
News Explained
Treace reports up to
Key Figures
- Q3 revenue
- $48.3 million, down 4%
- Third quarter 2026 versus third quarter 2025
- Net loss
- $12.6 million, improved 23%
- Third quarter 2026
- Adjusted EBITDA
- $0.3 million
- Third quarter 2026, compared with a $2.6 million loss in 2025
- Operating expenses
- $49.9 million, down 10%
- Third quarter 2026 versus third quarter 2025
- Year-to-date cash usage
- Reduced 53%, or $9.7 million
- Compared with the same period in 2025
- Cash, cash equivalents, and marketable securities
- $39.8 million
- As of September 30, 2026
- 2026 revenue guidance
- $206 million to $210 million
- Full-year 2026; represents a 3% to 1% decline versus 2025
- 2026 Adjusted EBITDA outlook
- $1.0 million to $2.0 million loss
- Full-year 2026; prior expected loss range was $3.0 million to $5.0 million
Previous Earnings Reports
-
Raised 2026 revenue outlook and narrowed expected Adjusted EBITDA loss range.
-
Reported Q3 2025 revenue and EBITDA figures used as current-year comparison.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adjusted ebitda financial
non-gaap financial measures financial
prospective, multicenter study medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Achieved double digit procedure volume growth in the third quarter
PONTE VEDRA, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions, today reported financial results for the third quarter ended September 30, 2026.
Recent Highlights
- Generated revenue of
$48.3 million in the third quarter 2026. - Improved third quarter 2026 net loss by
23% to$(12.6) million , and Adjusted EBITDA by$2.9 million to$0.3 million when compared to the prior year period. - Reduced year-to-date cash usage by
53% or$9.7 million when compared to the same period in 2025. Cash, cash equivalents, and marketable securities totaled$39.8 million as of September 30, 2026. - Announced 5-Year results of a prospective, multicenter study demonstrating long term, positive outcomes of the Lapiplasty® procedure; a first-in-industry milestone for a commercial instrumented bunion correction system.
- Increased adoption of expanded bunion portfolio with approximately
45% of Lapiplasty® surgeon users now incorporating one or more of the Company’s three new bunion systems launched in the third quarter 2025, up from40% in the second quarter of 2026.
“We are encouraged by our third quarter performance, reflecting accelerated double-digit case volume growth and continued market share gains – driven by increasing adoption of our comprehensive range of best-in-class bunion systems, as well as our expanding portfolio of new technologies including our SuperBite™ compression screws. These new product offerings are allowing us to penetrate a much broader range of our surgeon customers’ most common foot and ankle procedures,” said John T. Treace, CEO and Chairman of Treace Medical. “We continue to make disciplined investments in key growth initiatives with an emphasis on our product pipeline, while staying focused on improving profitability and reducing cash usage. We believe this balanced approach positions us to build momentum and deliver stronger growth to finish the year.”
Third Quarter 2026 Financial Results
Revenue for the third quarter of 2026 was
Gross profit for the third quarter of 2026 was
Total operating expenses decreased
Third quarter 2026 net loss decreased by
Year-to-date cash usage was reduced by
2026 Financial Outlook
The Company is updating its full-year 2026 revenue guidance to be in the range of
The Company is updating its expectation of a loss in Adjusted EBITDA to be in the range of
The Company reiterates its expectation for a reduction in cash usage of approximately
The Company’s full-year 2026 guidance assumes continued case volume growth and improving year-over-year revenue growth rates.
Webcast and Conference Call Details
Treace will host a conference call today, November 6, 2026, at 8:00 a.m. ET to discuss its third quarter 2026 financial results. Investors interested in listening to the conference call may do so by registering. The live webcast of the conference call will be available on the Investor Relations section of the Company’s website at investors.treace.com. The webcast will be archived on the website following the completion of the call.
Use of Non-GAAP Financial Measures
To supplement the financial results presented in accordance with GAAP, this earnings release presents Adjusted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs, restructuring costs, customer credit loss, litigation costs, and debt extinguishment loss. Non-GAAP financial measures such as Adjusted EBITDA are presented in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management uses non-GAAP financial measures to evaluate the Company’s operating performance and trends, as well as for making planning decisions. The Company believes that Adjusted EBITDA helps to identify underlying trends in the Company’s business that may otherwise be masked by the effect of the income and expenses and other items that it excludes in its calculation of Adjusted EBITDA. Accordingly, the Company believes this non-GAAP financial measure provides useful information to investors and others in understanding and evaluating the Company’s operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by the Company’s management in their financial and operational decision-making. The Company also presents this non-GAAP financial measure because it believes investors, analysts and rating agencies consider it to be a useful metric in measuring the Company’s performance against other companies and its ability to meet its debt service obligations.
There are limitations related to the use of non-GAAP financial measures such as Adjusted EBITDA because they are not prepared in accordance with GAAP, may exclude significant income and expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation between GAAP and non-GAAP results is presented below.
*A reconciliation of Adjusted EBITDA to GAAP net loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.
Forward-Looking Statements
This press release and statements made during the Company’s earnings call contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s: 2026 full-year guidance; anticipated liquidity; 2026 Adjusted EBITDA guidance; expected 2026 cash usage decrease; anticipated building momentum and delivery of stronger growth to finish the year; anticipated continued case volume growth; expected increase in product adoptions, portfolio utilization and market share; continued execution of commercial and other strategic initiatives; ability to effectively respond to and mitigate the impact of challenges in the current market environment, including in response to increased competition, evolving surgeon and patient preferences for minimally invasive bunion solutions, changes in tariffs and trade policies, supply chain disruptions, protracted government and infrastructure shutdowns, and lower patient demand for elective bunion surgery due to macroeconomic uncertainty and soft consumer sentiment; anticipated future product launches and the timing of such product launches; ability to increase procedure volumes, expand surgeon relationships and utilization rate, and increase procedure penetration and market share; ability to protect and enforce its intellectual property rights, including through its patent infringement and unfair competition suits; success in defending against securities class actions and infringement of its intellectual property by third parties, including its competitors; expected seasonality; ability to leverage investments in its commercial organization and control costs in its organizational structure and to effectively and appropriate engage with and utilize consulting surgeons; anticipated expansion of clinical evidence; the amount and timing of orders for our products from stocking distributors and other customers; ability to obtain an adequate supply of materials and components, including from single-source or foreign suppliers; the impact of cybersecurity attacks or breaches, including attacks facilitated by artificial intelligence; and anticipated pace of growth in the foot and ankle market. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 27, 2026, and Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. The Company’s results for the quarter ended September 30, 2026 are not necessarily indicative of its operating results for any future periods.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty® 3D Minimally Invasive Bunion Correction System and the Percuplasty® Percutaneous 3D Bunion Correction System, and the SpeedMTP® MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate® rapid compression implant platform to new applications, providing surgeons with advanced digital solutions with its IntelliGuide® patient specific, pre-op planning and cut guide technology, and offering SuperBite™ fully-threaded compression screws for use in fusions throughout the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net
| Treace Medical Concepts, Inc. Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | 48,253 | $ | 50,214 | $ | 140,827 | $ | 150,171 | ||||||||
| Cost of goods sold | 9,903 | 10,508 | 29,463 | 30,820 | ||||||||||||
| Gross profit | 38,350 | 39,706 | 111,364 | 119,351 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Sales and marketing | 29,708 | 34,421 | 94,423 | 103,627 | ||||||||||||
| Research and development | 4,492 | 4,680 | 13,490 | 15,740 | ||||||||||||
| General and administrative | 15,682 | 16,281 | 47,108 | 48,216 | ||||||||||||
| Total operating expenses | 49,882 | 55,382 | 155,021 | 167,583 | ||||||||||||
| Loss from operations | (11,532 | ) | (15,676 | ) | (43,657 | ) | (48,232 | ) | ||||||||
| Interest income | 387 | 634 | 1,333 | 2,250 | ||||||||||||
| Interest expense | (1,584 | ) | (1,338 | ) | (4,716 | ) | (3,970 | ) | ||||||||
| Other income, net | 163 | 92 | 640 | 344 | ||||||||||||
| Other non-operating income (expense), net | (1,034 | ) | (612 | ) | (2,743 | ) | (1,376 | ) | ||||||||
| Net loss | $ | (12,566 | ) | $ | (16,288 | ) | $ | (46,400 | ) | $ | (49,608 | ) | ||||
| Other comprehensive income (loss) | ||||||||||||||||
| Unrealized gain (loss) on marketable securities | (56 | ) | 33 | (180 | ) | (14 | ) | |||||||||
| Comprehensive loss | $ | (12,622 | ) | $ | (16,255 | ) | $ | (46,580 | ) | $ | (49,622 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.19 | ) | $ | (0.26 | ) | $ | (0.71 | ) | $ | (0.79 | ) | ||||
| Weighted-average shares used in computing net loss per share, basic and diluted | 65,464,832 | 63,515,372 | 65,038,981 | 63,069,810 | ||||||||||||
| Treace Medical Concepts, Inc. Balance Sheets (in thousands, except share and per share amounts) (unaudited) | ||||||||
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 7,760 | $ | 10,708 | ||||
| Marketable securities, short-term | 32,038 | 37,659 | ||||||
| Accounts receivable, net of allowance for credit losses of | 30,219 | 42,155 | ||||||
| Inventories | 42,304 | 36,031 | ||||||
| Prepaid expenses and other current assets | 6,365 | 5,501 | ||||||
| Total current assets | 118,686 | 132,054 | ||||||
| Property and equipment, net | 33,037 | 29,752 | ||||||
| Intangible assets, net of accumulated amortization of | 6,412 | 7,125 | ||||||
| Goodwill | 12,815 | 12,815 | ||||||
| Operating lease right-of-use assets | 6,917 | 7,614 | ||||||
| Other non-current assets, net of allowance for credit losses of | 1,433 | 1,221 | ||||||
| Total assets | $ | 179,300 | $ | 190,581 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 14,284 | $ | 6,726 | ||||
| Accrued liabilities | 7,244 | 5,784 | ||||||
| Accrued commissions | 7,524 | 9,365 | ||||||
| Accrued compensation | 10,545 | 6,331 | ||||||
| Other liabilities | 6,482 | 2,429 | ||||||
| Total current liabilities | 46,079 | 30,635 | ||||||
| Long-term debt, net | 56,264 | 55,583 | ||||||
| Operating lease liabilities, net of current portion | 12,622 | 13,982 | ||||||
| Other long-term liabilities | 2,689 | 3,049 | ||||||
| Total liabilities | 117,654 | 103,249 | ||||||
| Stockholders’ equity | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 66 | 64 | ||||||
| Additional paid-in capital | 358,904 | 337,371 | ||||||
| Accumulated deficit | (295,392 | ) | (248,992 | ) | ||||
| Accumulated other comprehensive income (loss) | (108 | ) | 72 | |||||
| Treasury stock, at cost; 348,299 and 165,513 shares as of September 30, 2026 and December 31, 2025, respectively | (1,824 | ) | (1,183 | ) | ||||
| Total stockholders’ equity | 61,646 | 87,332 | ||||||
| Total liabilities and stockholders’ equity | $ | 179,300 | $ | 190,581 | ||||
| Treace Medical Concepts, Inc. Statements of Cash Flows (in thousands) (unaudited) | ||||||||
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (46,400 | ) | $ | (49,608 | ) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities | ||||||||
| Depreciation and amortization expense | 4,819 | 7,815 | ||||||
| Provision for allowance for credit losses | 363 | 512 | ||||||
| Share-based compensation expense | 21,428 | 26,268 | ||||||
| Non-cash lease expense | 1,637 | 1,689 | ||||||
| Amortization of debt issuance costs | 747 | 223 | ||||||
| Amortization (accretion) of premium (discount) on marketable securities, net | 15 | (119 | ) | |||||
| Other, net | 1,766 | 750 | ||||||
| Net changes in operating assets and liabilities, net of acquisitions | ||||||||
| Accounts receivable | 11,573 | 7,428 | ||||||
| Inventory | (6,273 | ) | (2,169 | ) | ||||
| Prepaid expenses and other assets | (864 | ) | (531 | ) | ||||
| Other non-current assets | (272 | ) | (303 | ) | ||||
| Operating lease liabilities | (1,034 | ) | (2,382 | ) | ||||
| Accounts payable | 7,558 | 5,581 | ||||||
| Accrued liabilities | 3,833 | (3,191 | ) | |||||
| Other, net | 391 | 93 | ||||||
| Net cash provided by (used in) operating activities | (713 | ) | (7,944 | ) | ||||
| Cash flows from investing activities | ||||||||
| Purchases of available-for-sale marketable securities | (26,181 | ) | (34,889 | ) | ||||
| Sales and maturities of available-for-sale marketable securities | 31,607 | 49,593 | ||||||
| Purchases of property and equipment | (7,434 | ) | (11,119 | ) | ||||
| Net cash provided by (used in) investing activities | (2,008 | ) | 3,585 | |||||
| Cash flows from financing activities | ||||||||
| Proceeds from insurance premium financing | 899 | 1,553 | ||||||
| Debt issuance costs | (6 | ) | — | |||||
| Payments on insurance premium financing | (586 | ) | (507 | ) | ||||
| Proceeds from exercise of employee stock options | 107 | 476 | ||||||
| Taxes from withheld shares | (641 | ) | (827 | ) | ||||
| Net cash provided by (used in) financing activities | (227 | ) | 695 | |||||
| Net increase (decrease) in cash and cash equivalents | (2,948 | ) | (3,664 | ) | ||||
| Cash and cash equivalents at beginning of period | 10,708 | 11,350 | ||||||
| Cash and cash equivalents at end of period | $ | 7,760 | $ | 7,686 | ||||
| Supplemental disclosure of cash flow information | ||||||||
| Cash paid for interest | $ | 3,529 | $ | 3,754 | ||||
| Noncash investing activities | ||||||||
| Unrealized (gains) losses, net on marketable securities | $ | 180 | $ | 14 | ||||
| Noncash financing activities | ||||||||
| Legal cost financing | $ | 1,723 | $ | 752 | ||||
| Treace Medical Concepts, Inc. Reconciliation of GAAP Net Loss to EBITDA & Adjusted EBITDA (in thousands) (unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net loss | $ | (12,566 | ) | $ | (16,288 | ) | $ | (46,400 | ) | $ | (49,608 | ) | ||||
| Adjustments: | ||||||||||||||||
| Interest income | (387 | ) | (634 | ) | (1,333 | ) | (2,250 | ) | ||||||||
| Interest expense | 1,584 | 1,338 | 4,716 | 3,970 | ||||||||||||
| Taxes | — | — | — | — | ||||||||||||
| Depreciation & Amortization | 2,032 | 2,778 | 4,819 | 7,815 | ||||||||||||
| EBITDA | $ | (9,337 | ) | $ | (12,806 | ) | $ | (38,198 | ) | $ | (40,073 | ) | ||||
| Share-based compensation expense | 6,931 | 7,998 | 21,428 | 26,268 | ||||||||||||
| Restructuring costs1 | — | 1,177 | 1,009 | 1,177 | ||||||||||||
| Litigation costs2 | 2,715 | 1,038 | 7,037 | 2,548 | ||||||||||||
| Adjusted EBITDA | $ | 309 | $ | (2,593 | ) | $ | (8,724 | ) | $ | (10,080 | ) | |||||
1 Restructuring charges primarily related to severance payments and other post-employment benefits.
2 Litigation costs related to intellectual property lawsuits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Treace Medical Concepts’ third-quarter 2026 revenue and earnings?
Treace reported $48.3 million in revenue, down 4% year over year, and a net loss of $12.6 million, or $0.19 per share. The prior-year quarter had a net loss of $16.3 million, or $0.26 per share. Adjusted EBITDA improved to positive $0.3 million from a $2.6 million loss.
What is TMCI’s updated full-year 2026 financial outlook?
Treace expects revenue of $206 million to $210 million and an adjusted EBITDA loss of $1 million to $2 million for 2026. Previous ranges were $204 million to $212 million and a $3 million to $5 million loss, respectively. The expected reduction in cash usage remains approximately 50% versus 2025.
What assumptions underpin Treace Medical Concepts’ 2026 guidance?
Treace’s full-year 2026 guidance assumes continued case volume growth and improving year-over-year revenue growth rates.